SEC Comment Letter for Forma Therapeutics Holdings, Inc. (CIK 0001538927) — Nov 17, 2020
Forma Therapeutics Holdings, Inc. (CIK 0001538927)
Date: Nov. 17, 2020 · CIK: 0001538927 · Accession: 0000000000-20-010998
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo November 17, 2020 Frank D. Lee Chief Executive Officer Forma Therapeutics Holdings, Inc. 500 Arsenal Street, Suite 100 Watertown, MA 02472 Re:Forma Therapeutics Holdings, Inc. Draft Registration Statement on Form S-1 Submitted November 13, 2020 CIK No. 0001538927 Dear Mr. Lee: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Gabriella Morales-Rivera, Esq.
Show Raw Text
United States securities and exchange commission logo
November 17, 2020
Frank D. Lee
Chief Executive Officer
Forma Therapeutics Holdings, Inc.
500 Arsenal Street, Suite 100
Watertown, MA 02472
Re:Forma Therapeutics Holdings, Inc.
Draft Registration Statement on Form S-1
Submitted November 13, 2020
CIK No. 0001538927
Dear Mr. Lee:
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Gabriella Morales-Rivera, Esq.